 |
Journal articles
A galactosidase-responsive doxorubicin-folate conjugate for selective targeting of acute myelogenous leukemia blasts
Abstract : Cytarabine combined with an anthracycline or an anthracenedione represents the usual intensive induction therapy for the treatment of AML. However, this protocol induces severe side effects and treatment-related mortality due to the lack of selectivity of these cytotoxic agents. In this paper, we present the study of the first galactosidase-responsive molecular "Trojan Horse" programmed for the delivery of doxorubicin exclusively inside AML blasts over-expressing the folate receptor (FR). This targeting system allows the selective killing of AML blasts without affecting normal endothelial, cardiac or hematologic cells from healthy donors suggesting that FDC could reduce adverse events usually recorded with anthracyclines.
Cited literature [40 references]
https://www.hal.inserm.fr/inserm-02444614
Contributor : Sylvain Fraineau Connect in order to contact the contributor
Submitted on : Saturday, January 18, 2020 - 11:19:47 AM
Last modification on : Tuesday, February 1, 2022 - 10:02:03 AM
Long-term archiving on: : Sunday, April 19, 2020 - 12:43:05 PM
Contributor : Sylvain Fraineau Connect in order to contact the contributor
Submitted on : Saturday, January 18, 2020 - 11:19:47 AM
Last modification on : Tuesday, February 1, 2022 - 10:02:03 AM
Long-term archiving on: : Sunday, April 19, 2020 - 12:43:05 PM